The Global Perspective of Pharmacovigilance in Nuclear Medicine Practice.
作者信息
Meher Bikash Ranjan, Agrawal Kanhaiyalal, Padhy Biswa Mohan
机构信息
Department of Pharmacology, All India Institute of Medical Sciences, Sijua, Bhubaneswar, Odisha, India.
Department of Nuclear Medicine, All India Institute of Medical Sciences, Sijua, Bhubaneswar, Odisha, India.
出版信息
Indian J Nucl Med. 2018 Oct-Dec;33(4):269-272. doi: 10.4103/ijnm.IJNM_103_18.
Abstract
摘要
相似文献
1
The Global Perspective of Pharmacovigilance in Nuclear Medicine Practice.
Indian J Nucl Med. 2018 Oct-Dec;33(4):269-272. doi: 10.4103/ijnm.IJNM_103_18.
2
[Pharmacovigilance of Chinese medicine: practice of cognition, application, prevention and rescue of drug toxicity].
Zhongguo Zhong Yao Za Zhi. 2017 May;42(10):2017-2020. doi: 10.19540/j.cnki.cjcmm.20170307.007.
3
Pharmacovigilance in perspective.
Drug Saf. 1999 Dec;21(6):429-47. doi: 10.2165/00002018-199921060-00001.
4
Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
Vaccine. 2012 Jul 13;30(33):4953-9. doi: 10.1016/j.vaccine.2012.05.045. Epub 2012 May 30.
5
A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia.
Saudi Med J. 2015 Sep;36(9):1097-102. doi: 10.15537/smj.2015.9.12125.
6
Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance database.
Ann Pharmacother. 2015 Jan;49(1):39-47. doi: 10.1177/1060028014558153. Epub 2014 Nov 3.
7
Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
Clin Ther. 2019 Nov;41(11):2252-2262. doi: 10.1016/j.clinthera.2019.08.018. Epub 2019 Sep 20.
8
Advances in pharmacovigilance initiatives surrounding antimicrobial resistance-Indian perspective.
Expert Opin Drug Saf. 2016 Aug;15(8):1055-62. doi: 10.1080/14740338.2016.1182495. Epub 2016 May 13.
9
Belgian community pharmacists' pharmacovigilance perspective and practice.
Res Social Adm Pharm. 2019 Dec;15(12):1446-1452. doi: 10.1016/j.sapharm.2019.01.007. Epub 2019 Jan 10.
10
Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective.
J Ethnopharmacol. 2012 Apr 10;140(3):519-25. doi: 10.1016/j.jep.2012.01.058. Epub 2012 Feb 21.
引用本文的文献
1
Adverse events associated with the use of radiopharmaceuticals: A prospective study from a tertiary care institute.
Perspect Clin Res. 2025 Apr-Jun;16(2):87-91. doi: 10.4103/picr.picr_89_24. Epub 2024 Sep 10.
2
Adverse Reactions by Radiopharmaceuticals: Retrospective Analysis of the Portuguese National Pharmacovigilance System.
Ann Pharmacother. 2025 Oct;59(10):919-927. doi: 10.1177/10600280251316542. Epub 2025 Feb 23.
3
Pharmacovigilance of Radiopharmaceuticals: Challenges and Opportunities.
J Pharm Technol. 2024 Oct;40(5):257-259. doi: 10.1177/87551225241266172. Epub 2024 Jul 27.
4
Review of Adverse Reactions Associated with the Use of Common Diagnostic Radiopharmaceuticals.
Indian J Nucl Med. 2021 Apr-Jun;36(2):163-167. doi: 10.4103/ijnm.ijnm_219_20. Epub 2021 Jun 21.
5
A Comparative Study of Pharmacopoeial Quality Standards and Regulations of Radiopharmaceuticals.
Indian J Nucl Med. 2021 Apr-Jun;36(2):153-162. doi: 10.4103/ijnm.ijnm_222_20. Epub 2021 Jun 21.
6
How can we optimise the pharmaceutical analysis of radiopharmaceutical pediatric prescriptions?
Eur J Hosp Pharm. 2023 Jan;30(1):29-34. doi: 10.1136/ejhpharm-2020-002473. Epub 2021 May 7.
7
Inclusion of Radiopharmaceuticals in the Indian Pharmacopeia: A Step Forward.
Indian J Nucl Med. 2020 Jan-Mar;35(1):1-3. doi: 10.4103/ijnm.IJNM_133_19. Epub 2019 Dec 31.
8
Vaccine pharmacovigilance in India: Current context and future perspective.
Indian J Pharmacol. 2019 Jul-Aug;51(4):243-247. doi: 10.4103/ijp.IJP_53_19.
9
Ethical Conundrum in Nuclear Medicine Research in India.
Indian J Nucl Med. 2019 Apr-Jun;34(2):83-85. doi: 10.4103/ijnm.IJNM_171_18.
本文引用的文献
1
Theranostics in nuclear medicine practice.
Onco Targets Ther. 2017 Oct 3;10:4821-4828. doi: 10.2147/OTT.S140671. eCollection 2017.
2
[The 38th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 41st Survey in 2015)].
Kaku Igaku. 2017;54(1):509-519. doi: 10.18893/kakuigaku.rp.1772.
3
Evaluation of Radiopharmaceutical Adverse Reaction Reports to the British Nuclear Medicine Society from 2007 to 2016.
J Nucl Med. 2017 Dec;58(12):2010-2012. doi: 10.2967/jnumed.117.194092. Epub 2017 May 18.
4
Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Curr Radiopharm. 2017;10(1):6-15. doi: 10.2174/1874471009666161229123126.
5
Pharmacovigilance in radiopharmaceuticals.
Indian J Nucl Med. 2016 Apr-Jun;31(2):89-92. doi: 10.4103/0972-3919.178252.
6
A questionnaire based study to assess knowledge, attitude and practice of pharmacovigilance among undergraduate medical students in a Tertiary Care Teaching Hospital of South India.
Perspect Clin Res. 2015 Oct-Dec;6(4):217-21. doi: 10.4103/2229-3485.167102.
7
Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance database.
Ann Pharmacother. 2015 Jan;49(1):39-47. doi: 10.1177/1060028014558153. Epub 2014 Nov 3.
8
Therapeutic radionuclides in nuclear medicine: current and future prospects.
J Zhejiang Univ Sci B. 2014 Oct;15(10):845-63. doi: 10.1631/jzus.B1400131.
9
A portable database of adverse reactions and drug interactions with radiopharmaceuticals.
J Nucl Med Technol. 2013 Sep;41(3):212-5. doi: 10.2967/jnmt.113.120626. Epub 2013 Jul 15.
10
Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome.
Endocr Rev. 2012 Dec;33(6):920-80. doi: 10.1210/er.2012-1030. Epub 2012 Sep 7.
Zotero 插件